Alexandra Balcom insider trades

Open-market stock purchases and sales by Alexandra Balcom, Chief Financial Officer at Nuvalent, Inc, from SEC Form 4 filings since Jan 4, 2022.

Recent trades

DateStockTradeValue
Jul 1, 2026NUVL Nuvalent, IncSold$1.4M
Jul 1, 2026NUVL Nuvalent, IncBought (not open market)—
Jul 1, 2026NUVL Nuvalent, IncBought (not open market)—
Jun 2, 2026CBIO Crescent Biopharma, IncBought (not open market)—
Jun 1, 2026NUVL Nuvalent, IncSold$91.1K
Jun 1, 2026NUVL Nuvalent, IncSold$208K
Jun 1, 2026NUVL Nuvalent, IncSold$313K
Jun 1, 2026NUVL Nuvalent, IncSold$260K
Jun 1, 2026NUVL Nuvalent, IncSold$20.8K
Jun 1, 2026NUVL Nuvalent, IncBought (not open market)—
Jun 1, 2026NUVL Nuvalent, IncSold$87.9K
Jun 1, 2026NUVL Nuvalent, IncSold$118K
Jun 1, 2026NUVL Nuvalent, IncSold$28.4K
May 1, 2026NUVL Nuvalent, IncBought (not open market)—
May 1, 2026NUVL Nuvalent, IncBought (not open market)—
May 1, 2026NUVL Nuvalent, IncSold$381K
May 1, 2026NUVL Nuvalent, IncSold$738K
May 1, 2026NUVL Nuvalent, IncSold$12.4K
Apr 1, 2026NUVL Nuvalent, IncSold$370K
Apr 1, 2026NUVL Nuvalent, IncSold$570K
Apr 1, 2026NUVL Nuvalent, IncSold$262K
Apr 1, 2026NUVL Nuvalent, IncBought (not open market)—
Mar 25, 2026NUVL Nuvalent, IncSold$1.4M
Mar 24, 2026NUVL Nuvalent, IncSold$735K
Mar 24, 2026NUVL Nuvalent, IncSold$112K

Companies traded

  • NUVL Nuvalent, Inc: 81 sales, last Jul 1, 2026
  • CBIO Crescent Biopharma, Inc: other filings, last Jun 2, 2026

Get free alerts when Alexandra Balcom files a new trade →